[Antihypertensive therapy with co-dergocrine mesilate/nifedipine in comparison with nifedipine in type II diabetes].
In a randomized cross-over study the antihypertensive effects of nifedipine and the combination of co-dergocrine and nifedipine (Pontuc) respectively as well as the influence of both preparations on the glucose metabolism was tested in 22 hypertensive patients with diabetes type II over a period of 4 weeks. During treatment with the combination a significantly more pronounced blood pressure reduction was achieved compared to monotherapy with nifedipine, whereas the heart rate was significantly increased only by nifedipine. Both drugs--nifedipine and co-dergocrine/nifedipine--did not change the concentrations of glucose in the blood or urine or of HbA1.
Janka
H U
HU
Zentralkrankenhaus Bremen-Nord, Klinikum für Innere Medizin, Bremen.
Mehnert
H
H
D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006029:Glycosuria / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*
D001786:Blood Glucose; D004088:Dihydroergotoxine; D006442:Glycated Hemoglobin; D009543:Nifedipine
Antihypertensive Therapie mit Co-Dergocrinmesilat/Nifedipin im Vergleich mit Nifedipin bei Typ-II-Diabetes.